ArticleUrology practice2026
The Reality of Benign Prostatic Hyperplasia Surgery Price and Reimbursement Across Top United States Hospitals.
Article in Urology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionA growing number of surgical treatments are available for benign prostatic hyperplasia (BPH), each with distinct clinical profiles and resource demands. Wide variations in cost and reimbursement are understood to exist because of hospital-insurer negotiations, but are rarely quantified. The 2021 Medicare Price Transparency final rule now provides publicly available pricing data, allowing objective evaluation of real-world costs. We used these data to assess hospital charges and commercial reimbursement for common BPH procedures.
methodsCharges and commercial reimbursement were obtained from the Turquoise Health database, which compiles pricing reported under Medicare transparency regulations. We analyzed procedure type, hospital, payer class, and service location among US News Top 20 hospitals.
resultsCharges varied by procedure; the highest median charge was associated with transurethral waterjet ablation ($15,742 [$11,281-$27,707]) and the lowest with prostatic urethral lift ($4489 [$1228-$46,289]). Private insurers were associated with higher charges. Significant interhospital variation was observed for prostatic urethral lift (
conclusionsSubstantial variation in BPH procedure pricing and reimbursement persists across top-ranked hospitals despite Medicare's price transparency regulations. Price variation seems more influenced by nonprocedural factors, highlighting inequities in institutional negotiations and the need for further evaluation of hospital pricing patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.